China Vanke Co., Ltd. (Stock Code: 2202) convened the twenty-sixth meeting of its twentieth session of the board of directors on 30 October 2025, where nine directors participated. The meeting was deemed to have met all relevant regulatory and procedural requirements.

The board approved the 2025 Third Quarterly Report and Financial Statements, disclosing that China Vanke recognized or added RMB9,367.9452 million in impairment provisions in the third quarter of 2025, predominantly from new provisions for inventory impairment totaling RMB9,192.5974 million. During the same period, RMB1,708.2637 million of existing provisions were reversed or written off.

As of 30 September 2025, total impairment provisions stood at RMB53,914.8913 million, marking a rise of RMB7,659.6815 million compared to the end of the interim period of 2025.